We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Smartphone-Enabled, Paper-Based Quantitative Diagnostic Platform Transforms POC Testing

By LabMedica International staff writers
Posted on 08 Oct 2024

Point-of-care diagnostics are crucial for public health, offering rapid, on-site testing that enables prompt diagnosis and treatment. More...

This is especially valuable in remote or underserved regions where access to laboratory resources is limited. By enabling immediate clinical decisions, point-of-care testing can alleviate strain on healthcare systems and enhance patient outcomes. Now, a new study has demonstrated the effectiveness of a smartphone-enabled, paper-based quantitative diagnostic platform, which improves point-of-care diagnostics by delivering enhanced accuracy, real-time data, and broader accessibility for fast and reliable testing.

The study focused on HueDx’s (Pennsylvania, PA, USA) innovative platform, which comprises HueTools and HueLab. HueDx’s HueTools are artificial intelligence (AI) tools that shorten assay development from years to months while its HueLab customizable cartridge and app, create a portable testing solution that eliminates the need for a traditional lab. This research represents a significant breakthrough in colorimetric diagnostic methods, overcoming past challenges in achieving accurate and consistent results in clinical chemistry at the point of care without requiring additional hardware. The incorporation of smartphone technology enhances these capabilities, allowing for the quantification of previously qualitative assays and enabling real-time data collection and analysis. This will expand point-of-care testing to more providers, including at-home testing, delivering quantitative and actionable results.

The study found that the color correction system restored images to near-perfect consistency, independent of original illumination conditions. In precision testing, the coefficient of variation was nearly twice as high without the color correction. Additionally, limits of blank, detection, and quantification were significantly improved using the HueDx pipeline. The research also demonstrated the platform's effectiveness in calibrating and quantifying a paper-based total protein assay, illustrating its potential for use in point-of-care testing across diverse medical settings.

“The HueDx color correction system represents a major leap forward in diagnostic technology, allowing for accurate and reliable testing in real-world settings,” said Dr. Nidhi Menon, Head of R&D, at HueDx, Inc. “We’re dedicated to enhancing health outcomes with innovative solutions, and our work truly reflects that commitment, setting the stage for the future of smartphone-enabled diagnostics.”

Related Links:
HueDx


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Platelet Function Analyzer
PL-12
Pipette Calibration System
Artel PCS®
New
Fully Automated Urinalysis System
DxU 1800 Fully Automated Urinalysis System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

Single Genetic Analysis Identifies Causes of Premature Ovarian Insufficiency

Premature ovarian insufficiency (POI) affects up to 3.5% of women and represents a major cause of infertility. In most cases, the underlying etiology remains unknown, making patient counseling and clinical... Read more

Microbiology

view channel
Image: The “broth” used to monitor red blood cell depletion in whole blood spiked with one colony-forming-unit of E. coli bacteria, each incubated at different orbital shaking speeds—left to right: 0 RPM, 65 RPM, 120 RPM and 200 RPM—after four hours of incubation. This culturing raises a bacteria-rich, plasma-like layer of bacteria to the top of the vials, while clusters of stuck blood cells known as a Rouleaux formation sink to the bottom. (Image Credit: Pak Kin Wong)

New Diagnostic Workflow Identifies Bloodstream Pathogens and Antibiotic Response in Hours

Sepsis is a life-threatening complication of infection that affects more than 1.5 million patients annually in the United States and contributes to roughly one in three in-hospital deaths.... Read more

Pathology

view channel
Image: Researchers evaluated AI models that quantify tumor-infiltrating lymphocytes (TIL) on routine breast tissue slides, where higher TIL levels reflect stronger antitumor response and improved breast cancer outcomes (Image Credit: Shutterstock)

AI Matches Pathologists in Predicting Breast Cancer Prognosis from Immune Cells

Breast cancer is the most common cancer in Australian women, with more than 20,000 cases each year. Prognosis can be informed by counting tumor-infiltrating lymphocytes (TILs) on routine pathology slides,... Read more

Industry

view channel
Image: RaDaR ST uses a tumor-informed approach that identifies up to 48 patient-specific variants through whole-exome sequencing and tracks those variants in plasma to detect circulating tumor DNA (ctDNA) at very low variant allele fractions (VAFs) (Photo courtesy of Neogenomics)

Tumor-Informed MRD Assay Gains Medicare Coverage for Immunotherapy Monitoring

NeoGenomics’ RaDaR ST molecular residual disease (MRD) assay has received expanded coverage from the Centers for Medicare & Medicaid Services’ Molecular Diagnostic Services Program (MolDX) for monitoring... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.